Progenics to narrow focus to oncology, cut staff by 26%
This article was originally published in Scrip
Executive Summary
Progenics Pharmaceuticals has unveiled plans, following a strategic review, to become leaner and more nimble, and it will reduce its head count by 38, or 26% and narrow its research area to oncology.